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The telomeric protein TRF2 is required to prevent mammalian telomeres from activating DNA damage checkpoints.
Here we show that overexpression of TRF2 affects the response of the ATM kinase to DNA damage. Overexpression of
TRF2 abrogated the cell cycle arrest after ionizing radiation and diminished several other readouts of the DNA damage
response, including phosphorylation of Nbs1, induction of p53, and upregulation of p53 targets. TRF2 inhibited
autophosphorylation of ATM on S1981, an early step in the activation of this kinase. A region of ATM containing S1981
was found to directly interact with TRF2 in vitro, and ATM immunoprecipitates contained TRF2. We propose that TRF2
has the ability to inhibit ATM activation at telomeres. Because TRF2 is abundant at chromosome ends but not
elsewhere in the nucleus, this mechanism of checkpoint control could specifically block a DNA damage response at
telomeres without affecting the surveillance of chromosome internal damage.
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dependent DNA damage response. PLoS Biol 2(8): e240.
Introduction
Telomeres prevent the recognition of natural chromosome
ends as double-stranded breaks (DSBs). When telomeres
become dysfunctional due to shortening or loss of protective
factors, chromosome ends activate a DNA damage response
mediated (in part) by the ATM kinase (Karlseder et al. 1999;
Takai et al. 2003). A major challenge in telomere biology is to
deﬁne the mechanism by which functional telomeres prevent
these events. Here we show that the human telomere-
associated protein TRF2 is an inhibitor of the ATM kinase,
suggesting a mechanism by which the telomeric protein
complex prevents the activation of this DNA damage
response transducer.
TRF2 is a small multimeric protein that binds to duplex
telomeric (TTAGGG) repeats and recruits hRap1, ERCC1/
XPF, WRN, and the Mre11/Rad50/Nbs1 complex to chromo-
some ends (Li et al. 2000; Zhu et al. 2000, 2003; Opresko et al.
2002; Machwe et al. 2004). TRF2 can be inhibited with a
dominant-negative allele, TRF2
DBDM, which removes the
endogenous TRF2 complex from telomeres (van Steensel et
al. 1998). Upon expression of TRF2
DBDM, telomeres become
uncapped and experience a series of deleterious events,
including association with DNA damage response factors
such as 53BP1, cleavage of the telomeric 39 overhang by
ERCC1/XPF, and telomere–telomere ligation by DNA ligase
IV (van Steensel et al. 1998; de Lange 2002; Smogorzewska et
al. 2002; Takai et al. 2003; Zhu et al. 2003). The DNA damage
response to uncapped telomeres induces phosphorylation of
DNA damage response proteins, including H2AX, SMC1,
Rad17, CHK1, and CHK2, and upregulation of p53, p21, and
p16, resulting in a G1 arrest (Karlseder et al. 1999;
Smogorzewska and de Lange 2002; d’Adda di Fagagna et al.
2003). Primary human cells with telomere damage undergo
apoptosis or senescence (Karlseder et al. 1999; Smogorzewska
and de Lange 2002).
An important transducer of the DNA damage signal is the
ATM kinase (reviewed in Shiloh 2003). ATM activation
requires autophosphorylation on S1981 and concomitant
dissociation into monomers, the presumed active form of the
kinase (Bakkenist and Kastan 2003). DSBs and other genome
stress lead to a rapid conversion of the ATM pool into active
S1981–P monomers, which can phosphorylate regulators of
the G1/S, intra-S, and G2/M cell cycle transitions (Bakkenist
and Kastan 2003).
Activation of ATM also takes place in response to telomere
damage. When telomeres become uncapped due to inhibition
of TRF2, S1981-phosphorylated ATM associates with telo-
meres (Takai et al. 2003). Furthermore, ATM targets become
phosphorylated in aging cells with shortened telomeres
(d’Adda di Fagagna et al. 2003). Genetic evidence for a role
of ATM in the telomere damage pathway is provided by the
diminished ability of ataxia telangiectasia (A-T) cells to
mount a DNA damage response after telomere uncapping
(Karlseder et al. 1999; Takai et al. 2003). However, several
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linositol 3-kinase-like kinase), such as ATR or DNA-PKcs, can
transduce the telomere damage signal in the absence of ATM
(Takai et al. 2003; Wong et al. 2003).
One proposed mechanism of telomere protection is based
on the ciliate telomere proteins, which envelop the single-
stranded telomere terminus (Horvath et al. 1998). Such a
protein cap, if sufﬁciently stable, could simply hide chromo-
some ends from the DNA damage surveillance machinery.
Both budding and ﬁssion yeast also contain protective single-
stranded telomere-binding proteins, but it is not known
whether these proteins function similarly by forming a
physical cap over the telomere terminus (Garvik et al. 1995;
Baumann and Cech 2001).
TRF2 must represent a different mechanism for telomere
protection since it only binds to the duplex part of the
telomere. TRF2 has been proposed to promote the formation
of t-loops (Grifﬁth et al. 1999; Stansel et al. 2001). In the
t-loop conﬁguration, the 39 overhang of TTAGGG repeats is
strand-invaded into the duplex part of the telomere.
Although this could be an effective way to protect chromo-
some ends from nucleases and ligases, t-loops have several
structural features resembling DNA lesions, including single
strand to double strand transitions, 39 and 59 ends, and single-
stranded DNA. Therefore, human telomeres may need
additional mechanisms to circumvent checkpoint activation.
The results presented here argue for a model in which TRF2
directly blocks activation of the ATM kinase.
Results
TRF2 was overexpressed in IMR90 primary ﬁbroblasts
using a retroviral vector. Under these conditions, TRF2
saturates its telomeric binding sites and is present in the
nucleoplasm. While control IMR90 cells showed the expected
reduction in mitotic index after ionizing radiation (IR), TRF2
overexpression partially abrogated this checkpoint response,
increasing the percentage of cells entering mitosis from 0.3%
to 8% (Figure 1). The inappropriate entry into mitosis is
indicative of a failure of the cell cycle checkpoints. Since cell
cycle arrest after IR largely depends on ATM (reviewed in
Shiloh 2003), we asked whether TRF2 was acting on this
kinase. Caffeine, an inhibitor of ATM and the related kinase
ATR, suppressed IR-induced arrest to a similar extent as
TRF2 (Figure 1). Furthermore, caffeine had no additional
effect on the ability of TRF2-overexpressing cells to bypass
the DSB checkpoint, suggesting that TRF2 and caffeine target
the same step in the response pathway.
We then asked whether TRF2 overexpression inhibited
other ATM-dependent readouts of the DNA damage re-
sponse. ATM phosphorylates and stabilizes p53 in response to
DNA damage (reviewed in Kastan and Lim 2000). Quantita-
tive immunoblotting showed that cells overexpressing TRF2
had a diminished ability to induce p53 after irradiation
(Figures 2A and 2B). Both the relative level of p53 protein and
the induction of its downstream targets p21, Bax, and Hdm2
were dampened. By contrast, the p16/Rb pathway was not
affected by TRF2 (Figure 2A). We also examined the
phosphorylation of Nbs1 on S343, a target of ATM (Gatei et
al. 2000; Lim et al. 2000; Wu et al. 2000; Zhao et al. 2000).
Phosphorylation of this residue causes a change in electro-
phoretic mobility shift and can also be detected using an
antibody speciﬁc for the phosphorylated form of Nbs1.
Extracts from irradiated control cells showed the previously
reported retardation of Nbs1 and its reactivity with the S343–
P-speciﬁc Nbs1 antibody (Figure 2C). Both alterations could
be reversed by phosphatase treatment of the Nbs1 immuno-
precipitations (IPs). In contrast, irradiation did not appear to
induce phosphorylation of Nbs1 in cells overexpressing
TRF2, indicating that TRF2 diminished the ATM-dependent
phosphorylation of Nbs1 (Figure 2C).
Because TRF2 overexpression blunted several cellular
responses that depend (in part) on the ATM kinase, we
determined TRF2’s effect on the activation of ATM itself.
Phosphorylation of ATM on S1981, an early and essential step
in the activation of this kinase, can be detected rapidly after
IR, even when a low level of DNA damage is induced
(Bakkenist and Kastan 2003). To test whether TRF2 affected
the autophosphorylation of ATM, the two proteins were
expressed in 293T cells and ATM was activated with low doses
of IR. TRF2 inhibited the activation of ATM as monitored by
immunoblotting with an antibody speciﬁc for ATM S1981–P
(Figure 3A). The relative level of ATM S1981–P (normalized
to total ATM protein) at 0.3 Gy was 49% of the vector control
value (p = 0.002, Student’s t test; n = 7). The TRF2 paralog
TRF1, which also binds the duplex telomeric repeats, did not
have a signiﬁcant effect on ATM activation, demonstrating
Figure 1. TRF2 Inhibits the IR-Induced Cell Cycle Arrest
(A) Retrovirally infected IMR90 cells were treated with 4 Gy IR (left
and right) or treated with 4 Gy IR and exposed to caffeine (10 mM)
directly after irradiation (middle). After 16 h, during which the cells
were incubated in 1 lg/ml colcemide, the DNA was stained with DAPI
and mitotic cells were identiﬁed by immunoﬂuorescence with an
antibody to phosphorylated histone H3.
(B) Quantiﬁcation of bypass of IR-induced cell cycle arrest. The mean
percentage of phosphorylated histone H3-positive cells and SDs from
three experiments are given. The low maximal incidence of
phosphorylated H3-positive nuclei (approximately 18%) is due to
loss of mitotic cells during processing; loss of mitotic cells occurred at
the same level in control and experimental samples.
DOI: 10.1371/journal.pbio.0020240.g001
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Overexpression of TRF2 also diminished the IR-induced
ATM autophosphorylation of endogenous ATM in IMR90
ﬁbroblasts to 55% of vector control value at 0.3 Gy and 60%
of vector control value at 0.6 Gy (Figure 3B).
In order to understand the mechanism by which TRF2
inhibited ATM, we determined whether they interacted in
vivo. IPs of the ATM kinase from primary human IMR90
ﬁbroblasts resulted in recovery of a small fraction (approx-
imately 1%) of endogenous TRF2 (Figure 4A). This associa-
tion was accentuated when TRF2 was overexpressed from a
retroviral vector. TRF2 was not recovered in anti-ATM
immunoprecipitates from A-T cells even when TRF2 was
overexpressed (Figure 4A), demonstrating that the recovery
of TRF2 is dependent on the presence of functional ATM.
The co-IP of TRF2 with ATM from IMR90 cells was resistant
to the addition of ethidium bromide (data not shown),
arguing that DNA tethering is not responsible for the
association. A control IP with antibodies to the CycD1/
Cdk4/Cdk6 kinase complex did not precipitate TRF2, and an
irrelevant nuclear protein (Nova1), overexpressed in parallel
in IMR90 cells, was not recovered in the ATM IP (Figure 4A).
The association of TRF2 with ATM was not dependent on the
presence of DNA damage, since neither IR nor UV treatment
enhanced the recovery of TRF2 in ATM IPs (data not shown).
The nature of the association of TRF2 with ATM was
explored further using in vitro pulldown experiments. GST-
tagged fragments of ATM were tested for their ability to bind
puriﬁed TRF2 protein expressed in a baculovirus system. In
parallel, we used baculovirus-derived TRF1, which was
previously shown to interact with ATM by co-IP (Kishi et al.
2001). TRF2 bound to two overlapping fragments of ATM
spanning amino acids 1439 to 2138 (Figure 4B). This region
contains the FAT domain and S1981, the critical target of
autophosphorylation (Bakkenist and Kastan 2003). TRF1
bound a different region of ATM (Figure 4B), demonstrating
the speciﬁcity of the observed interactions.
Blunting of the DNA damage response was observed when
TRF2 was overexpressed throughout the nucleus. Because
TRF2 is chieﬂy present at telomeres, the simplest interpre-
tation is that the observed activity reﬂected a telomeric
function. However, we also considered the possibility that
TRF2 may have a heretofore clandestine role in the general
Figure 2. Effect of TRF2 on Downstream Readouts of the IR-Induced ATM
Response
(A) Retrovirally infected IMR90 cells were exposed to 5 Gy IR and
harvested after 0, 12, 24, and 36 h. Levels of p53, Bax, p21, Hdm2, p16,
pRB, and c-tubulin (loading control) were detected by immunoblot-
ting of equal cell number equivalents.
(B) Amount of p53 protein at the indicated timepoints (hours) was
determined by densitometry of p53 immunoblots such as shown in
(A). Amounts were normalized to the vector control at 0 h. Mean
values from three experiments and standard deviations are shown.
(C) Retrovirally infected IMR90 cells were exposed to 20 Gy IR and
harvested after 45 min. Nbs1 was immunoprecipitated and sub-
sequently detected by immunoblotting using a general Nbs1 antibody
and a phosphospeciﬁc Nbs1 S343 antibody. IPs were treated with k-
phosphatase where indicated.
DOI: 10.1371/journal.pbio.0020240.g002
Figure 3. Effect of TRF2 on IR-Induced ATM Phosphorylation
(A) Overexpression of TRF2 inhibits IR-induced phosphorylation of
transfected ATM in 293T cells. 293T cells co-transfected with ATM
and either TRF2, TRF1, or vector were treated with the indicated
doses of IR. After a 30-min recovery, cells were harvested and
immunoblot analysis was performed on whole-cell lysates.
(B) Overexpression of TRF2 inhibits IR-induced phosphorylation of
endogenous ATM in primary ﬁbroblasts. IMR90 primary ﬁbroblasts
infected with a retroviral construct expressing TRF2 or an empty
virus were treated with the indicated doses of IR. After a 1 h recovery,
cells were harvested and ATM was immunoprecipitated from whole-
cell lysates. Immunoblot analysis was performed on immunoprecipi-
tated ATM.
DOI: 10.1371/journal.pbio.0020240.g003
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expected to localize to IR-induced foci (IRIF), where it would
be in a position to modulate ATM. Previous data had shown
that the endogenous TRF2 does not relocate from telomeres
to IRIF (Zhu et al. 2000). Similarly, immunoﬂuorescence
analysis showed that overexpressed TRF2 did not form IRIF
(Figure 4C): the pattern of TRF2 localization was unchanged
by IR, and there was no detectable colocalization with the
known IRIF component 53BP1 (Schultz et al. 2000). This was
also the case when TRF2 localization was examined in cells
from which the nucleoplasmic proteins were extracted with a
mild detergent (Figure 4C). Thus, the inhibitory effect of
TRF2 on ATM signaling does not reﬂect association of TRF2
with sites of DNA damage. Instead, we propose that the
inhibition of ATM by TRF2 is an innate property of the
protein, important at its natural location: telomeres. How-
ever, we cannot exclude the transient presence of TRF2 at
DNA lesions and/or a role for TRF2 in the general DNA
damage response.
Discussion
Natural chromosome ends require mechanisms to prevent
the activation of the DNA damage response. Inhibition of the
Figure 4. TRF2 Interacts with the ATM
Kinase In Vivo and In Vitro and TRF2 Does
Not Localize to IRIF
(A) Co-IP of TRF2 with ATM. Protein
extracts from IMR90 cells and A-T cells
(AG02496) infected with an empty virus
or a TRF2-overexpressing virus were
incubated with anti-ATM or anti-Cyclin
D1 antibodies as indicated, and TRF2
was detected in the IP pellets by immu-
noblotting. The right panel represents
IPs with anti-ATM antibodies from
IMR90 cells infected with a retrovirus
overexpressing Nova1 or the empty
vector and detection of Nova1 by im-
munoblotting. For each extract 1% of
the IP input (input) was processed for
immunoblotting in parallel.
(B) Bacterially expressed ATM–GST fu-
sion proteins were puriﬁed on gluta-
thione agarose beads and visualized by
Western blotting with anti-GST antibody
(Upstate Biotechnology [Lake Placid,
New York, United States] #06–332)
(top). Unfused GST was run on a
separate gel because of its low molecular
weight. Equal amounts of fusion proteins
and GST alone were incubated with
puriﬁed baculoviral TRF2 (middle) or
TRF1 (bottom), bound to glutathione
beads, spun down, washed, and bound
proteins were processed for immuno-
blotting with an anti-TRF1 or anti-TRF2
serum.
(C) TRF2 does not localize to IRIFS.
IMR90 primary ﬁbroblasts infected with
a retroviral construct expressing TRF2
or an empty virus were treated with 5 Gy
IR. After a 90 min recovery, cells were
ﬁxed and processed for immunoﬂuores-
cence with or without Triton X-100
extraction before ﬁxation. Arrowheads
denote foci of TRF2 signal previously
demonstrated to represent telomeres.
When overexpressed, some TRF2 is
localized to nucleolus.
DOI: 10.1371/journal.pbio.0020240.g004
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since the telomeric complex contains the Mre11 complex,
one of the DNA damage sensors of the ATM pathway (Carson
et al. 2003; Petrini and Stracker 2003; Uziel et al. 2003). The
telomeric protein TRF2 appears to play a central role in
preventing telomeres from activating ATM. Removal of TRF2
from telomeres results in the localization of the active,
phosphorylated form of ATM to unprotected chromosome
ends (Takai et al. 2003) and induces ATM-dependent
apoptosis (Karlseder et al. 1999). The data reported here
are consistent with the hypothesis that TRF2 protects
telomeres through a direct interaction with ATM that blocks
its activation. As a result, TRF2 abrogates the downstream
outcomes of the ATM-dependent DNA damage response,
including phosphorylation of various ATM targets and cell
cycle arrest.
We feel that the interaction of TRF2 with ATM is likely to
be relevant to the mechanism by which TRF2 blocks ATM
signaling. TRF2 binds ATM in a region surrounding S1981,
which is functionally linked to the oligomerization state of
ATM. Phosphorylation on S1981 occurs concomitant with the
dissociation of ATM dimers (or oligomers), forming the
monomeric, active form of the kinase (Bakkenist and Kastan
2003). TRF2 is also an oligomer of four to eight subunits,
which are held together by the TRFH dimerization domain as
well as other, yet to be deﬁned, protein interactions (Broccoli
et al. 1997; Fairall et al. 2001; Stansel et al. 2001). Owing to its
oligomeric nature, TRF2 could potentially cross-link ATM
monomers and thus hold the kinase in its inactive dimeric (or
oligomeric) state. In this manner, TRF2 could abrogate the
ATM pathway since it would block ampliﬁcation of the ATM
signal at an early step. In agreement with this idea, the in
vitro GST pulldown experiments showed that TRF2 can
interact with ATM when it is not phosphorylated on S1981.
Because mutations in the TRF2 dimerization domain desta-
bilize the protein, it has not been possible to test the
contribution of TRF2 oligomerization on ATM repression
directly. Alternatively, the interaction of TRF2 with the
region surrounding S1981 may prevent ATM autophosphor-
ylation or TRF2 binding could block a presumed interaction
between ATM and a DNA damage sensor, such as the Mre11
complex. It is unlikely that TRF2 acts as an ATM target
mimetic that titrates out genuine ATM targets since TRF2 is
not a target of the ATM kinase (R. Drissi, M. B. Kastan, and J.
Dome, unpublished data). Furthermore, TRF2 does not block
ATM kinase activity in an in vitro assay (S. Kozlov, J.
Karlseder, and M. F. Lavin, unpublished data). These ﬁndings
are consistent with TRF2 acting at one of the earlier steps in
the activation of the ATM kinase, including the interplay
between ATM and DNA damage sensors, ATM autophos-
phorylation, or dissociation of ATM dimers.
In this study we have expressed TRF2 at high levels
throughout the nucleus, whereas endogenous TRF2 is
localized primarily to telomeres (van Steensel et al. 1998).
Our estimates suggest that TRF2 is extremely abundant at
telomeres. Human cells contain on the order of 1 million
copies of TRF2 (X.-D. Zhu and T. de Lange, unpublished
data), sufﬁcient to position thousands of TRF2 molecules at
each chromosome end. This number is consistent with the
presence of thousands of TRF2-binding sites per telomere
and the oligomerization potential of the protein. Thus, for
every ATM kinase that could be activated at a chromosome
end, there is a vast molar excess of its potential inhibitor,
TRF2. Since TRF2 is speciﬁcally lodged at telomeres and
remains there when DNA damage is induced, it is unlikely to
interfere with activation of the ATM kinase at sites of DNA
damage elsewhere in the genome. Hence, TRF2 could act as a
telomere-speciﬁc inhibitor of ATM.
Previous studies have shown that overexpression of TRF2
can protect critically short telomeres generated by replicative
aging (Karlseder et al. 2002). TRF2 reduced the incidence of
end-to-end chromosome fusions in this setting and also
delayed the onset of senescence. These ﬁndings suggested
that senescence is induced by an altered telomere state, in
which the telomere has become so short that the amount of
TRF2 it can recruit is insufﬁcient for the protection of the
chromosome end. When TRF2 is overexpressed, this deﬁ-
ciency in TRF2 recruitment may be overcome. One possibility
is that the altered state of critically short telomeres
represents a situation in which telomeres have a diminished
ability to form t-loops. The current ﬁndings raise the
possibility that the altered state may also include a situation
in which the telomere contains insufﬁcient TRF2 to repress
ATM. However, the ability of TRF2 to delay senescence was
also observed in A-T cells (Karlseder et al. 2002), indicating
that ATM repression is not the only pathway by which
increased TRF2 loading can protect critically short telomeres.
As TRF2 can bind ATM, it has the inherent ability to
recruit this protein to telomeres. ATM has not been observed
at undamaged telomeres, but its abundance may be too low
for detection. The idea that ATM could be recruited to
telomeres by TRF2 is interesting considering that ATM-like
kinases are necessary for telomere maintenance in Saccha-
romyces cerevisiae (Craven et al. 2002) and Schizosacchar-
omyces pombe (Matsuura et al. 1999). It is not excluded that
human telomere maintenance similarly requires ATM. TRF2
could function to recruit ATM in an inactive form, perhaps
allowing for highly regulated activation of ATM at appro-
priate times. Such regulation of DNA damage signaling and
repair pathways at telomeres has been proposed previously in
the context of the nonhomologous end-joining pathway and
the role of the nucleotide excision repair endonuclease
ERCC1/XPF (Smogorzewska et al. 2002; Zhu et al. 2003). In
both cases, proteins with the potential to have detrimental
effects on telomeres appear to be regulated such that their
activities can be employed for telomere function.
Materials and Methods
Cell culture and IR treatment. IMR90 primary lung ﬁbroblasts
(ATCC, Manassas, Virginia, United States) and AG02496 and
AG04405 primary A-T ﬁbroblasts (Coriell Cell Repository, Camden,
New Jersey, United States; PD 12 and PD 15) were grown and infected
with retroviruses as described elsewhere (Karlseder et al. 2002). For c-
irradiation, 3 10
5 cells were seeded in 5-cm culture dishes and
exposed to a Ce137 source. Where indicated, the medium was replaced
with medium containing 10 mM caffeine (Sigma, St. Louis, Missouri,
United States) and 1 lg/ml colcemide (Sigma). Indirect immuno-
ﬂuorescence was performed as described (Smogorzewska et al. 2000;
Takai et al. 2003).
Co-transfection assay for S1981–P inhibition. One day prior to
transfection, approximately 5 10
6 293T cells were plated in 10-cm
dishes. Cells were transfected with 1 lg of FLAG–ATM DNA (Canman
et al. 1998) and 9 lg of N-terminally Myc-tagged TRF2 (Karlseder et
al. 2002) or TRF1 in a pLPC vector backbone (gift of S. Lowe, Cold
Spring Harbor Laboratory) or vector alone using CaPO4 coprecipi-
tation. Two days after transfection, cells were harvested in media and
divided into three equal fractions, which were exposed to 0, 0.3, or 0.6
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resuspended in 250 ll of lysis buffer (50 mM Tris [pH 7.4], 1% Triton
X-100, 0.1% SDS, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM
PMSF, with a complete mini-protease inhibitor tablet [Roche, Basel,
Switzerland] per 10 ml). The NaCl concentration was raised to 400
mM, and the lysate was incubated on ice for 5 min. The NaCl
concentration was reduced to 200 mM, cell debris was removed by
centrifugation, and an equal volume of Laemmli buffer was added to
the lysate.
Immunoblotting. For ATM immunoblots in the ATM S1981–P
suppression assays: 40 ll of 293T cell lysate or ATM immunopreci-
pitated from approximately 5 10
6 IMR90 ﬁbroblasts were run on 7.5%
precast polyacrylamide Bio-Rad (Hercules, California, United
States) Ready Gels. PVDF Immobilon
TM Transfer Membrane (Milli-
pore, Billerica, Massachusetts, United States) was prepared for protein
transfer according to the manufacturer’s instructions and the gel was
transferred for 2 h at 90 V. Membranes were preincubated in 10%
milk, 0.1% Tween-20 in PBS for 30 min at room temperature and
subsequently incubated with primary antibodies: polyclonal rabbit
ATM S1981–P (Bakkenist and Kastan 2003) and mouse monoclonal
ATM antibody MAT3 (gift from Y. Shiloh) diluted in 0.1% milk, 0.1%
Tween-20 in PBS overnight at 4 8C followed by three 10 min washes.
Membranes were incubated for 45 min with HRP-conjugated
secondary antibodies, washed, and developed using the ECL system
(Amersham, Little Chalfort, United Kingdom). Immunoblots of Myc-
tagged proteins (using Ab-1; Oncogene Research, Cambridge, Massa-
chusetts, United States) in the ATM S1981–P suppression assays were
performed as above, except that nitrocellulose (Schleicher and
Schuell, Keene, New Hampshire, United States) ﬁlters were used.
For all other immunoblots, cells were trypsinized, washed once with
PBS, and subsequently lysed in Laemmli buffer at 10
4 cells/ll. Lysates
(10 ll) were separated on SDS-polyacrylamide gels (29:1 acrylamide:
bisacrylamide, 8% for p53, TRF2, and c-tubulin, 6% for pRB and
Hdm2, 12% for Bax, p21, and p16) and transferred onto nitrocellulose
membranes (Schleicher and Schuell) for 60 min at 90 V (Bio-Rad Mini-
Protean II Cell). Membranes were preincubated in 10% nonfat dry
milk, 0.1% Tween-20 in PBS for 30 min and subsequently incubated
with primary antibodies: p53 D01 (Santa Cruz Biotechnology, Santa
Cruz,California,UnitedStates);TRF2 serum647(Zhu etal. 2000);pRB
#554136 (PharMingen, Uppsalla, Sweden); Hdm2 #3F3 (gift from, A.
Levine); Bax #sc-7480 (Santa Cruz Biotechnology); p21 sc-7480 (Santa
Cruz Biotechnology); p16 #15126E (PharMingen); c-tubulin GTU88
(Sigma); Nova1 (Luque et al. 1991) in 5% dry milk, 0.1% Tween-20 in
PBS overnight. Secondary antibody incubation and ECL were
performed as described above. To quantify signals, band intensities
were determined using an AlphaImager
TM 2200 using the SpotDenso
function of AlphaEaseFC
TM Software Version 3.1.2 (Witec, Littau,
Switzerland).
IP. For co-IP of ATM and TRF2, proteins were extracted from
subconﬂuent cells by incubating trypsinized cells (approximately 10
7
cells/0.1 ml buffer) in 20 mM HEPES (pH 7.9), 0.42 M KCl, 25%
glycerol, 0.1 mM EDTA, 5 mM MgCl2, 0.2% NP40, 1 mM DTT, 0.5 mM
PMSF, 1 lg/ml leupeptine, 1 lg/ml aprotinin, 10 lg/ml pepstatin on
ice for 30 min. Debris was removed by centrifugation (14,000 rpm, 4
8C, 10 min). Protein concentration in the supernatant was deter-
mined using the Bradford assay and 400 lg of protein was diluted to
150 mM KCl and incubated for 20 min with 100 ll of protein G–
Sepharose beads (Amersham), blocked with 1% fetal bovine serum in
PBS. The beads were collected at 14,000 rpm for 1 min and the
supernatant was incubated with 5 lg of anti-ATM antibody (AB3,
Oncogene Research) or anti-Cyclin D1 antibody (#sc-6281, Santa
Cruz Biotechnology) for 1 h at 4 8C on a nutator. Protein G–
Sepharose beads (30 ll) were added, and the mixture was incubated 1
ha t48C on a nutator. The beads were collected at 4,000 rpm at 4 8C,
washed three times with wash buffer (150 mM NaCl, 1% NP40, 50 mM
Tris [pH 8.0] with protease inhibitors as described above) by
vortexing the suspension for 10 s. The beads were resuspended in
Laemmli buffer and boiled 5 min, and proteins were separated by
polyacrylamide gel electrophoresis. For IP of endogenous ATM from
IMR90 ﬁbroblasts for the phosphorylation assay, cells were resus-
pended in lysis buffer (50 mM Hepes [pH 7.5], 150 mM NaCl, 50 mM
NaF, 1% Tween-20, 0.2% NP40, 1mM PMSF, with 1 complete mini-
protease inhibitor tablet [Roche, Basel, Switzerland] ) and centrifuged
at 13,000 rpm for 10 min. 400 ll of lysate was incubated with 30 llo f
blocked protein G beads and 100 ll of D16.11 monoclonal super-
natant (Alligood et al. 2000) for 1.5 h. Beads were washed once in lysis
buffer and twice in RIPA buffer and resuspended in 60 ll of Laemmli
buffer.
Pulldown assays. GST–ATM fusion plasmids (Khanna et al. 1998)
were transformed into BL-21 cells. A 10-ml overnight culture was
used to inoculate 500 ml of LB-Amp (50 lg/ml) and at OD600, 0.5–0.7,
0.3 mM IPTG (ﬁnal) was added. After 3 h at 30 8C, cells were
harvested, resuspended in 8 ml of lysis buffer (50 mM Tris [pH 7.9],
100 mM KCl, 1% Triton X-100, 2 mM DTT, 0.1 mM PMSF, 1 complete
protease inhibitor tablet [Roche]) and sonicated three times for 30 s
on ice. The lysate was cleared by centrifugation at 50,000 g at 4 8C and
incubated with 600 ll of equilibrated glutathione beads for 2 h at 4
8C. The beads were washed three times for 10 min each (washes 1 and
3: PBS, 1% Triton X-100, 2 mM DTT, 0.1 mM PMSF, 1 mM
benzamidine, 1 complete protease inhibitor tablet [Roche]; wash 2:
300 mM NaCl, 50 mM Tris [pH 7.9], 2 mM DTT, 0.1 mM PMSF, 1 mM
benzamidine, 1 complete protease inhibitor tablet [Roche]) and a
fourth time in wash 4 (50 mM Tris [pH 7.9], 100 mM KCl, 10%
glycerol, 2 mM DTT, 0.1 mM PMSF). Fusion proteins were eluted in
500 ll of wash 4 containing 15 mM glutathione (reduced form). Two
subsequent elutions were collected. Five micrograms of GST fusion
proteins or GST alone were incubated with 2 lg of baculoviral TRF1
or TRF2 in binding buffer (150 mM NaCl, 100 mM KCl, 50 mM Tris
[pH 8.0], 1% NP40, 0.1% SDS, 100 g/ml BSA) at 4 8C for 1 h.
Glutathione beads (20 ll) were added and incubated for 1 h at 4 8C.
Beads were collected by centrifugation at 5,000 rpm at 4 8C and
washed three times for 10 min each with binding buffer, and bound
protein was eluted by boiling the samples in Laemmli buffer. GST
fusion proteins, TRF1, and TRF2 were detected by immunoblotting.
Cell cycle arrest assay. Cells were seeded on microscope coverslips
and irradiated with 4 Gy of c-irradiation as described above. Cells
were incubated in growth medium containing 1 lg/ml colcemid for 16
h. Cells were ﬁxed, and phosphorylated histone H3 was detected by
indirect immunoﬂuorescence using a phosphospeciﬁc antibody (6G3
monoclonal; Cell Signaling Technology, Beverly, Massachusetts,
United States). Cells in mitosis were counted and expressed as a
percentage of total cell number.
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